<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561157</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1102</org_study_id>
    <nct_id>NCT01561157</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of the Porphyrias</brief_title>
  <official_title>Longitudinal Study of the Porphyrias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to conduct a longitudinal multidisciplinary investigation&#xD;
      of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and&#xD;
      mortality in people with these disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The porphyrias are a group of rare metabolic diseases that may present in childhood or adult&#xD;
      life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common&#xD;
      manifestations are related to accumulation of intermediates in the pathway and usually occur&#xD;
      as acute neurological attacks, or cutaneous photosensitivity. Multiple mutations have been&#xD;
      identified in each of the porphyrias. The risk of disability or death from these disorders is&#xD;
      significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic&#xD;
      testing in clinical practice. Moreover, the natural history of these disorders is not well&#xD;
      described and it is not known what determines differences in outcomes. New therapies are&#xD;
      needed. For existing therapies, high-quality evidence on short and long term efficacy and&#xD;
      safety is generally lacking. Therefore, the purpose of this long-term follow-up study of a&#xD;
      large group of patients with the various porphyrias is to provide a better understanding of&#xD;
      the natural history of these disorders, as affected by available therapies, and to aid in&#xD;
      developing new forms of treatment.&#xD;
&#xD;
      The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a&#xD;
      Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes&#xD;
      and currently has funded several rare diseases clinical research consortia and one Data&#xD;
      Management and Coordinating Center. The Porphyrias Consortium was created as part of the&#xD;
      RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the&#xD;
      academic institutions listed in the participating institutions table. All Centers in the&#xD;
      Porphyrias Consortium are participating in the Longitudinal Study of the Porphyrias.&#xD;
      Additional centers may be added if funding is available.&#xD;
&#xD;
      The initial objective of this protocol is to assemble a well-documented group of patients&#xD;
      with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic&#xD;
      studies. The long-term objective is to conduct a longitudinal investigation of the natural&#xD;
      history, complications, and therapeutic outcomes in people with acute and cutaneous&#xD;
      porphyria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical analysis</measure>
    <time_frame>baseline</time_frame>
    <description>To develop disease severity scores to describe the combined frequency and severity of disease manifestations, utilizing linear mixed effects models &amp; stratification by age of onset.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory analysis</measure>
    <time_frame>baseline</time_frame>
    <description>To evaluate porphyrin and porphyrin precursor levels alone or by genotype and porphyria subtype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between disease severity and biomarkers</measure>
    <time_frame>baseline</time_frame>
    <description>To develop longitudinal models that relate, for example, porphyrin and porphyrin precursor levels alone or in concert with age, genotype and other features to the disease manifestation frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness and tolerability of currently used and new therapies for the human porphyrias</measure>
    <time_frame>baseline</time_frame>
    <description>Qualitative evaluation, using self-reporting questionnaires and clinical findings, and quantitative evaluation, using laboratory measures of organ function and porphyrin levels, to evaluate the effectiveness of therapies.</description>
  </secondary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Acute Porphyrias</condition>
  <condition>Cutaneous Porphyrias</condition>
  <arm_group>
    <arm_group_label>Acute Intermittent Porphyria (AIP)</arm_group_label>
    <description>Patients with a documented diagnosis of AIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary Coproporphyria (HCP)</arm_group_label>
    <description>Patients with a documented diagnosis of HCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Variegate Porphyria (VP)</arm_group_label>
    <description>Patients with a documented diagnosis of VP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Congenital Erythropoietic Porphyria (CEP)</arm_group_label>
    <description>Patients with a documented diagnosis of CEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatoerythropoietic Porphyria (HEP)</arm_group_label>
    <description>Patients with a documented diagnosis of HEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Porphyria Cutanea Tarda (PCT)</arm_group_label>
    <description>Patients with a documented diagnosis of PCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietic Protoporphyria (EPP)</arm_group_label>
    <description>Patients with a documented diagnosis of EPP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X-Linked Protoporphyria (XLP)</arm_group_label>
    <description>Patients with a documented diagnosis of XLP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)</arm_group_label>
    <description>Patients with a documented diagnosis of ALAD, ADP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous Dominant Acute Hepatic Porphyria</arm_group_label>
    <description>Patients with a documented diagnosis of Homozygous Dominant AHP</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma/serum, red blood cells, urine, tissue, DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the following resources:&#xD;
&#xD;
          1. Patients followed by one of the Investigators&#xD;
&#xD;
          2. The American Porphyria Foundation (APF)&#xD;
&#xD;
          3. Non-study Physician referrals&#xD;
&#xD;
          4. Self-referrals, including family members of individuals diagnosed with Porphyria&#xD;
             (proband) and other individuals who may have heard about the study from other subjects&#xD;
             or prospective subjects.&#xD;
&#xD;
          5. Medical Records Review&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with a documented diagnosis of a porphyria.&#xD;
&#xD;
          -  For each type of porphyria, the inclusion criteria are based on&#xD;
&#xD;
               -  Biochemical findings, as documented by laboratory reports (or copies) of&#xD;
                  porphyria-specific testing performed after 1980 (Absolute values are preferred&#xD;
                  for diagnostic biochemical thresholds. Fold increases in comparison to an upper&#xD;
                  (or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated&#xD;
                  by considerable variation between laboratories in normal limits. Equivocal&#xD;
                  biochemical measurements may require confirmation by a consortium reference&#xD;
                  laboratory;)&#xD;
&#xD;
               -  molecular findings documenting the identification of a mutation in a&#xD;
                  porphyria-related gene.&#xD;
&#xD;
          -  In addition, an individual or a parent or guardian must be willing to give written&#xD;
             informed consent or assent, as appropriate.&#xD;
&#xD;
          -  Provision is made for enrolling relatives who may not have symptoms but have&#xD;
             biochemical or molecular documentation of a porphyria, or in the case of recessive&#xD;
             disorders carry a disease-related mutation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other&#xD;
             diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone&#xD;
             marrow diseases;&#xD;
&#xD;
          -  Patients with a prior diagnosis of porphyria that cannot be documented by review of&#xD;
             existing medical records or repeat biochemical or DNA testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Desnick, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karli Hedstrom, MPH</last_name>
    <phone>212-659-1450</phone>
    <email>karli.hedstrom@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert J Desnick, MD, PhD</last_name>
    <phone>212-659-6700</phone>
    <email>robert.desnick@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Johnson</last_name>
      <phone>205-934-0498</phone>
      <email>angeliagjohnson@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Brendan McGuire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon Beaven, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuvraaj Kapoor</last_name>
      <phone>415-476-8405</phone>
      <email>yuvraaj.kapoor@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Jaffe, MSHE</last_name>
      <phone>305-243-9465</phone>
      <email>Dxj380@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Schaeffer, RN</last_name>
      <phone>312-355-1625</phone>
      <email>cdschaef@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Sean Quigley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haya Raef</last_name>
      <phone>207-766-1408</phone>
      <email>haya.raef@tufts.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Dickey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Eisenberg</last_name>
      <email>eisenbea@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Marshall Mazepa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Gonzalez</last_name>
      <phone>212-659-1418</phone>
      <email>nicole.gonzalez@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Manisha Balwani, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center and HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Faust</last_name>
      <phone>336-713-1442</phone>
      <email>delannin@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert L Bonkovsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Miller</last_name>
      <phone>215-955-8108</phone>
      <email>Cynthia.miller@Jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Manish Thapar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chandni Chaudhari, MD</last_name>
      <phone>409-747-4575</phone>
      <email>chchaudh@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Csilla Hallberg, MD</last_name>
      <phone>409-772-6287</phone>
      <email>challberg@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karl E. Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hina Yazdani</last_name>
      <phone>801-587-2506</phone>
      <email>hina.yazdani@hsc.edu</email>
    </contact>
    <investigator>
      <last_name>John Phillips, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niall Curley</last_name>
      <phone>206-288-1231</phone>
      <email>ncurley8@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Sioban Keel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rarediseasesnetwork.org/cms/porphyrias</url>
    <description>Website for the Rare Diseases Clinical Research Network (RDCRN) Porphyrias Consortium (PC</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Robert Desnick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>porphyria</keyword>
  <keyword>acute intermittent</keyword>
  <keyword>coproporphyria</keyword>
  <keyword>variegate</keyword>
  <keyword>erythropoietic</keyword>
  <keyword>protoporphyria</keyword>
  <keyword>hepatoerythropoietic</keyword>
  <keyword>cutanea tarda</keyword>
  <keyword>AIP</keyword>
  <keyword>HCP</keyword>
  <keyword>VP</keyword>
  <keyword>ADP</keyword>
  <keyword>ALAD</keyword>
  <keyword>PCT</keyword>
  <keyword>HEP</keyword>
  <keyword>CEP</keyword>
  <keyword>EPP</keyword>
  <keyword>XLP</keyword>
  <keyword>homozygous dominant</keyword>
  <keyword>acute hepatic</keyword>
  <keyword>AHP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyria, Acute Intermittent</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

